SONIC HEALTHCARE

MEDIA RELEASE – 20 August 2026

Sonic Healthcare delivers strong FY2026 result and achieves earnings guidance

Sydney, 20 August 2026 – Sonic Healthcare Limited (ASX: SHL ; ADR: SKHHY) today reported a strong financial and operational performance for the year ended 30 June 2026, achieving underlying EBITDA earnings guidance through strong revenue growth, operating leverage, and ongoing synergy realisation, whilst demonstrating disciplined capital management.

Highlights

A$m	FY2026	Growth
Revenue	**10,867**	***13%***
Underlying EBITDA	1,933	*11%*
Statutory EBITDA	1,882	*9%*
Underlying Net Profit	**621**	***17%***
Statutory Net Profit	608	18%
Underlying earnings per share (A¢)	125.6	*14%*
Statutory earnings per share (A¢)	123.0	*15%*

- Revenue growth of 13%, including strong organic growth of 5%
- EBITDA increased 11% and earnings per share increased 14% (underlying)
- LADR Laboratory Group acquisition completed and integration progressing well, with synergy realisation on schedule
- Continued substantial synergy capture from recent acquisitions in Switzerland
- Strong growth in advanced diagnostics, leveraging market-leading brands and capabilities across multiple geographies
- Completed sale and leaseback of the Brisbane hub laboratory as part of disciplined capital management program
- Commenced digital and AI transformation initiatives
- Progressive dividend maintained, increase of 1 cent to $1.08 per share total dividends for the year

Commentary

Sonic Healthcare's CEO, Dr Jim Newcombe, said: "Sonic Healthcare delivered a strong result in FY2026, achieving our earnings guidance while continuing to invest in future growth to create long-term value for shareholders. The result reflected the strength of our diversified global portfolio, our focus on operational excellence and the dedication of our people around the world.

"During my first nine months as CEO, I have seen first-hand the unique strengths that differentiate Sonic Healthcare. Sonic's investment proposition is clear: we deliver high-value medicine at scale, driving growth and financial performance. Our three key differentiators, scale and diversification, Medical Leadership and operational excellence, continue to underpin our performance and position us for future growth. Operating across nine countries and in 11 markets, Sonic is one of the world's leading medical diagnostics companies, providing essential medical services to over 140 million patients per year.

"The strength of our operating model was evident in FY2026. We achieved organic revenue growth of 5%, including strong growth in advanced diagnostics and realised substantial synergies from recent acquisitions in Germany and Switzerland. At the same time, we commenced a comprehensive operating review of our business in the United States and launched a significant program to modernise Sonic Healthcare's global digital infrastructure.

"Sonic Healthcare enjoys leading market positions, a proven operating model and a unique Medical Leadership culture. We remain focused on organic growth, efficiency, innovation and disciplined capital management, and are confident in our ability to deliver sustainable long-term value for shareholders. I would like to thank our 47,000 people globally for their commitment to caring for our communities. Their dedication remains the foundation of Sonic Healthcare's success."

For further information regarding this announcement, please contact:

Investor enquiries:
Elise Wang, Head of Investor Relations
Mobile: 0417 405 499
email: investor.relations@sonichealthcare.com

Media enquiries:
email: communications@sonichealthcare.com

This announcement has been authorised by the Board of Directors of Sonic Healthcare Limited – please refer to the contact details above.

For further information regarding the result, please refer to Sonic's FY2026 Financial and Operating Review Presentation and Sonic Healthcare's FY2026 Appendix 4E Preliminary Final Report, both of which will be posted on the Sonic Healthcare website by 10:00am on 20 August 2026.

Forward-looking statements

This media release may include forward-looking statements about Sonic Healthcare's financial results, guidance, business prospects and other future matters that may involve risks and uncertainties, many of which are outside the control of Sonic Healthcare. Forward-looking statements can generally be identified by the use of words such as "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "believe", "forecast", "estimate", "target", "outlook", "guidance" and other similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and reflect management's current estimates, projections, expectations or beliefs. Forward-looking statements are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks, uncertainties and other factors that could cause actual results, performance and outcomes to be materially different from those expressed, anticipated or implied by those statements.

Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse decisions by governments and healthcare regulators, changes in the competitive environment and billing policies, lawsuits, loss of contracts, unexpected growth in costs and expenses, changes in macroeconomic conditions, foreign exchange rates and capital market conditions, and additional risks and uncertainties not presently known to management or not currently considered material. The statements being made in this media release do not constitute an offer to sell, or solicitation of an offer to buy, any securities of Sonic Healthcare, nor do they constitute financial product, investment, legal, tax, accounting or other advice or a recommendation to acquire Sonic Healthcare securities. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person, including Sonic Healthcare. In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward-looking statement will be achieved.

Actual future events, results and outcomes may vary materially from the forward-looking statements and the assumptions on which the forward-looking statements are based. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. To the maximum extent permitted by law, Sonic Healthcare and its directors, officers, employees, agents and advisers disclaim any liability for any loss arising from use of, or reliance on, any forward-looking statement or other information in this media release. Except as required by law or regulation, including the ASX Listing Rules, Sonic Healthcare undertakes no obligation to update, revise or supplement any forward-looking statement, whether as a result of new information, future events, results or otherwise. The information provided in this media release is based on and should be read in conjunction with the Appendix 4E released to the ASX on 20 August 2026, Sonic Healthcare's 2025 Annual Report and other periodic and continuous disclosure announcements lodged with the ASX.

This media release includes certain financial measures presented on an "underlying" and/or "constant currency" basis which are not prepared in accordance with International Financial Reporting Standards (IFRS). These measures are used by management to assess the underlying performance of the business and should be considered in addition to, and not as a substitute for, financial information prepared in accordance with IFRS. Non-IFRS financial measures may not be directly comparable with similarly titled measures presented by other entities. A reconciliation of the underlying financial measures to the corresponding measures reported in accordance with IFRS is provided within the Appendix 4E.